	US 12,077,774 B2
	Method for enhancing the suppressive properties of Treg cells
Hans Stauss, London (GB); and Jenny L. McGovern, London (GB)
Assigned to UCL Business Ltd., London (GB)
Appl. No. 17/048,239
Filed by UCL Business Ltd., London (GB)
PCT Filed Apr. 17, 2019, PCT No. PCT/GB2019/051098 § 371(c)(1), (2) Date Oct. 16, 2020, PCT Pub. No. WO2019/202323, PCT Pub. Date Oct. 24, 2019.
Claims priority of application No. 1806330 (GB), filed on Apr. 18, 2018; and application No. 1806331 (GB), filed on Apr. 18, 2018.
Prior Publication US 2021/0079425 A1, Mar. 18, 2021
Int. Cl. C12N 15/87 (2006.01); A61K 35/12 (2015.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); C07K 14/725 (2006.01); C07K 14/74 (2006.01); C12N 5/0783 (2010.01)

CPC C12N 15/87 (2013.01) [A61K 35/17 (2013.01); C07K 14/7051 (2013.01); C07K 14/70539 (2013.01); C12N 5/0637 (2013.01); A61K 2035/122 (2013.01); A61K 38/00 (2013.01); C12N 2510/00 (2013.01)]

10 Claims

1. A pharmaceutical composition comprising an engineered regulatory T cell (Treg) with an enhanced ability to suppress immune responses obtained by a process comprising:

a) isolating a CD4⁺CD25⁺CD127⁻/lowCD45RA⁺ Treg from a cell population; and

b) introducing a polynucleotide encoding a FOXP3 polypeptide into the isolated CD4⁺CD25⁺CD127⁻/lowCD45RA⁺ Treg to enhance the ability of the Treg to suppress immune responses.